skip to main content

Early Ovarian Adjuvant — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateGynaecological CancersEarly Ovarian AdjuvantSCE Medical Oncology

A 45-year-old woman with FIGO stage IC1 high-grade serous ovarian cancer (intraoperative rupture) underwent optimal staging surgery. BRCA wild-type, HRD-negative. What adjuvant chemotherapy is recommended?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — 6 cycles of adjuvant carboplatin + paclitaxel

For high-grade serous ovarian cancer, adjuvant chemotherapy is recommended for all stages beyond IA/IB grade 1. Stage IC1 (intraoperative capsule rupture) with high-grade serous histology carries significant recurrence risk (~20-30%) and warrants 6 cycles of carboplatin-paclitaxel. The ICON1 trial supports adjuvant chemotherapy for early-stage high-risk ovarian cancer. PARP inhibitor maintenance is not standard for BRCA-WT/HRD-negative early-stage disease.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer